Recent Updates
Recently added Catalysts

ADHD: two biotech companies racing to a treatment

Neurology & PsychiatryConcentrated betData as of 2026-09-04

Competitors2in the clinic
Median market cap$6.7Buniverse median $1.20B
Allocated capital$3.4B$13.5B competing
Phase 3 or filed20 mid, 0 early
Pure plays0this indication only
Capital rank59/299crowding rank 77

ADHD is a two-horse race: Axsome Therapeutics (AXSM, $10.9B) against Supernus Pharmaceuticals (SUPN, $2.6B).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $3.4B of allocated capital sits on the pair.

AXSM alone accounts for 81% of the $13.5B of market capitalisation competing here, so this is a leader plus a tail rather than a level race.

$3.4B of allocated capital sits in ADHD, ranking it 59th of 299 indications by the money committed to it.

Companies developing drugs for ADHD 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AXSMAxsome TherapeuticsSolriamfetolPhase 35$10.9BNo4 31 Dec 2026
SUPNSupernus PharmaceuticalsSPN-812Phase 31$2.6BNo4No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile. AXSM holds 81% of the $13.5B competing in this indication.

Why ADHD is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. ADHD has 2 competitors and a median of $6.7B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

SCN2A Encephalopathy1 company · $3.3B · median $9.9BUncontestedTonic-Clonic Epilepsy1 company · $3.3B · median $9.9BUncontestedFriedreich Ataxia5 companies · $3.2B · median $941MOrphan cornerChronic Inflammatory Demyelinating Polyneuropathy2 companies · $3.6B · median $7.0BConcentrated betSpinal Muscular Atrophy Type III2 companies · $3.7B · median $4.6BConcentrated betTreatment Resistant Depression3 companies · $3.8B · median $1.8BConcentrated betAlzheimer's Disease5 companies · $2.9B · median $397MOrphan cornerExcessive Daytime Somnolence1 company · $2.7B · median $10.9BUncontested

ADHD pipeline questions

Which biotech companies are developing drugs for ADHD?

Axsome Therapeutics (AXSM, Solriamfetol, Phase 3); Supernus Pharmaceuticals (SUPN, SPN-812, Phase 3). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in ADHD.

How advanced is the ADHD pipeline?

Of the 2 clinical-stage programmes in ADHD, 2 are in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Which company leads the ADHD field?

AXSM is the largest developer in ADHD, holding 81% of the $13.5B of market capitalisation competing in the indication. The median competitor is worth $6.7B.

When is the next ADHD catalyst?

The next dated catalyst in ADHD is AXSM on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map